10-Q: Definitive Healthcare Reports Q2 Loss Amid Revenue Decline

Definitive Healthcare Corp. reported a net loss for Q2 2025, with revenue declining due to sales execution challenges and macroeconomic headwinds, despite a significantly lower goodwill impairment charge compared to the prior year.

Summary

• Net loss for the three months ended June 30, 2025, was $9.265 million, a significant improvement from the $306.187 million net loss in the same period of 2024.
• Revenue decreased by $3.0 million, or 5%, to $60.750 million for the three months ended June 30, 2025, compared to $63.737 million in Q2 2024.
• For the six months ended June 30, 2025, net loss was $164.358 million, down from $318.905 million in the prior year period.
• Six-month revenue decreased by $7.3 million, or 6%, to $119.941 million compared to $127.217 million in the first half of 2024.
• A non-cash, pre-tax goodwill impairment charge of $176.5 million was recorded in Q1 2025, significantly lower than the $363.6 million charge in Q1 2024.
• Customer count decreased to approximately 2,400 as of June 30, 2025, from 2,600 as of June 30, 2024.
• Enterprise Customer accounts (over $100,000 ARR) decreased by 27 to 510 as of June 30, 2025, from 537 as of June 30, 2024.
• Current Remaining Performance Obligations (cRPO) were $170.327 million as of June 30, 2025, down from $188.050 million as of December 31, 2024.
• The company repurchased 11.6 million shares of Class A Common Stock for $40.2 million under the 2025 Repurchase Program during the six months ended June 30, 2025.
• Cash and cash equivalents stood at $80.984 million, and short-term investments at $103.217 million as of June 30, 2025.
• Net cash provided by operating activities was $35.370 million for the six months ended June 30, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to declining revenue, customer churn, and acknowledged sales execution challenges. While the net loss significantly decreased, this was primarily due to a lower goodwill impairment charge rather than improved operational profitability. The company also explicitly forecasts continued revenue decline for the full year.

Positives

• Net loss significantly reduced to $9.265 million in Q2 2025 from $306.187 million in Q2 2024, primarily due to a lower goodwill impairment charge.
• No new goodwill impairment triggering events were identified in Q2 2025, indicating a stabilization compared to previous periods.
• The company maintains strong liquidity with $80.984 million in cash and cash equivalents and $103.217 million in short-term investments.
• A $100.0 million stock repurchase program is active, with $40.2 million already utilized, demonstrating commitment to shareholder returns.
• Successful renegotiation of an existing data contract resulted in one-time credits of approximately $1.9 million, reducing hosting and data costs.
• The Tax Receivable Agreement (TRA) liability decreased by $32.0 million, driven by remeasurement and payments.

Negatives

• Revenue declined by 5% in Q2 2025 and 6% for the six months ended June 30, 2025, primarily due to lower subscription revenue.
• Customer count decreased by 200 (from 2,600 to 2,400) year-over-year, with smaller customers churning at disproportionately higher rates.
• Enterprise Customer accounts decreased by 27, indicating challenges in retaining high-value clients.
• Current Remaining Performance Obligations (cRPO) decreased, suggesting a reduction in contracted future revenue.
• Sales execution challenges and macroeconomic headwinds, including lengthening deal cycles and more stringent approval processes, continue to impact new customer acquisition and upsell opportunities.
• Subscription renewals have not returned to historical levels, impacting revenue growth.
• Increased amortization expense from new data asset purchases and higher rates on certain technology assets contributed to higher cost of revenue.
• The company expects revenue to decline in 2025 compared with 2024.

Risks

• Risk of future goodwill impairments if market capitalization continues to decline or macroeconomic conditions worsen.
• Ongoing macroeconomic conditions, including fluctuating inflation, high interest rates, and geopolitical tensions, could negatively impact customer spending and deal cycles.
• Changes in the healthcare claims data market, including pricing, data availability, and use terms, may negatively impact data acquisition costs.
• Sales execution challenges and lower than historical renewal rates are expected to continue impacting results in 2025.
• The company's ability to obtain additional liquidity on reasonable terms or at all may be constrained by high interest rates, stock market volatility, or unfavorable macroeconomic conditions.
• Potential market-wide liquidity shortages due to adverse developments in financial institutions could impact the company's access to cash and ability to raise capital.
• Payments under the Tax Receivable Agreement are expected to be substantial and are subject to various factors, including timing of exchanges, stock price, and tax attributes.

Future Outlook

The company anticipates continued investment in cost of revenue, expecting it to modestly increase as new intelligence modules and products are added. Gross profit margin is expected to decrease in 2025 due to anticipated revenue declines and a largely fixed cost structure. Revenue is expected to decline in 2025 compared with 2024 due to ongoing macroeconomic challenges, sales execution issues, and lower subscription renewal rates. The company plans to continue investing in engineering and R&D to enhance its platform and will evaluate strategic acquisitions. Liquidity from cash flow, the credit facility, and existing cash/investments is believed to be sufficient for at least the next twelve months and long-term, though additional funding may be sought through debt or equity if needed.

Management Comments

• "We continuously monitor the direct and indirect impacts, and the potential for future impacts, of these circumstances on our business and financial results, as well as the overall global economy and geopolitical landscape."
• "Our reporting unit is at risk for future goodwill impairments if we experience a continued decline in our market capitalization or worsening macroeconomic conditions."
• "These changes [to go-to-market team] created disruptions to our sales efforts in 2024, impacting both new customer acquisition and upsell to existing customers."
• "These factors, in addition to the lower than historical renewal rates we observed through the second half of 2024 and the first half of 2025, have impacted, and we expect will continue to impact, our results in 2025."
• "Our smaller customers have churned at disproportionately higher rates, primarily due to current macroeconomic conditions."
• "We expect that our gross profit and gross margin will fluctuate from period to period depending on the interplay of these various factors. We expect that gross profit margin for 2025 will continue to be impacted by the expansion of data sources and the anticipated revenue declines, as described above."
• "Revenue declines, in combination with our largely fixed cost structure, are expected to result in a decrease in gross profit margin in 2025."
• "We do not believe inflation has had a material effect on our business, financial condition, or results of operations. However, if our costs were to become subject to significant inflationary pressures, we may not be able to fully offset higher costs through price increases and our inability or failure to do so could potentially harm our business, financial condition, and results of operations."

Industry Context

The healthcare commercial intelligence market is experiencing shifts, with data source disruptions affecting pricing, availability, and use terms for healthcare claims data. The broader macroeconomic environment, characterized by fluctuating inflation and high interest rates, is impacting business spending across industries, including healthcare, leading to lengthened deal cycles and more stringent approval processes for new and existing customers. This has particularly affected smaller customers and the Life Sciences market, contributing to heightened customer churn.

Comparison to Industry Standards

• The company's Net Dollar Retention Rate (NDR) is a key metric for SaaS companies, indicating customer expansion. While a specific current NDR value is not provided, the discussion of lower historical renewal rates and churn suggests performance below typical high-growth SaaS benchmarks.
• The decline in total customer count (from 2,600 to 2,400) and Enterprise Customer accounts (from 537 to 510) contrasts with the growth seen in many successful SaaS companies, particularly those in expanding markets.
• The goodwill impairment charges, while lower than the prior year, indicate a significant write-down of acquired value, which can be a red flag compared to industry peers that maintain asset values.
• The company's focus on a $10+ billion total addressable market and identification of over 100,000 potential customers suggests significant market opportunity, but current performance indicates challenges in capturing this potential compared to market leaders.

Management Changes

Corporate Governance

Legal Proceedings

• The company is subject to various legal proceedings, claims, and governmental inspections, audits, or investigations that arise in the ordinary course of business. Management believes the ultimate resolution of these matters would not have a material adverse effect on financial position, results of operations, or cash flows.

Related Party Transactions

• Revenue from entities affiliated with Sponsors and Board members was $0.1 million for Q2 2025 and $0.3 million for YTD Q2 2025, a decrease from prior year periods.
• Payments to related parties were $0.1 million for Q2 2025 and $0.4 million for YTD Q2 2025.
• Receivables for related party revenue transactions amounted to less than $0.1 million at June 30, 2025.
• Payables to related parties amounted to $0.2 million at June 30, 2025.

Stakeholder Impact

• Shareholders: Impacted by declining revenue and customer base, but potentially benefit from the ongoing stock repurchase program and reduced net loss (though largely due to lower impairment).
• Employees: Affected by executive transitions and past restructuring plans (2024 Restructuring Plan reduced workforce by ~150 people), which could impact morale and stability.
• Customers: Experiencing lengthened deal cycles and more stringent approval processes, indicating potential challenges in customer acquisition and retention.
• Creditors: The company remains compliant with financial covenants under its credit agreement, indicating continued ability to meet debt obligations.
• Suppliers (data providers): Changes in the healthcare claims data market, including pricing and data availability, could impact relationships and costs.

Next Steps

• Continue to invest in sales and marketing efforts and develop new use cases for the platform to drive new customer acquisition.
• Focus on expanding relationships with existing customers by adding functionality and use-cases across departments.
• Continue to invest significantly in engineering and research and development to enhance capabilities and functionality.
• Evaluate strategic acquisitions and investments that further expand the platform.
• Monitor for potential goodwill impairment indicators and potential impairments.
• Assess the impact of the One Big Beautiful Bill Act (OBBBA) on U.S. tax law changes and record any impacts in the period of enactment.

Key Dates

Recommendation

The company's core business performance is deteriorating, evidenced by declining revenue, a shrinking customer base (including Enterprise Customers), and lower subscription renewal rates. Management explicitly forecasts continued revenue decline for 2025. While the net loss decreased significantly, this was primarily due to a lower goodwill impairment charge, not a fundamental improvement in operational profitability. Ongoing macroeconomic headwinds and acknowledged sales execution challenges present significant obstacles to future growth. Despite sufficient liquidity and a stock repurchase program, the negative trends in key operational metrics suggest a challenging outlook, making a 'sell' recommendation prudent for investors seeking growth or stability.

Keywords

Healthcare intelligence, SaaS, SEC filing, 10-Q, Financial results, Revenue, Net loss, Goodwill impairment, Customer churn, Subscription services, Healthcare data, MedTech, Corporate governance, Stock repurchase, Tax Receivable Agreement